Relay Therapeutics (RLAY) Other Non-Current Liabilities (2021 - 2024)

Relay Therapeutics (RLAY) has 4 years of Other Non-Current Liabilities data on file, last reported at $11.4 million in Q1 2024.

• Other Non-Current Liabilities for Q1 2024 came in at $11.4 million, down 63.75% year-over-year; the trailing twelve-month figure through Mar 2024 was $11.4 million (down 63.75% YoY), and the FY2023 annual result was $13.2 million, down 59.21% from the prior year.
• Other Non-Current Liabilities fell to $11.4 million in Q1 2024 per RLAY's latest filing, from $13.2 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $50.5 million in Q3 2021 and troughed at $11.4 million in Q1 2024.
• A 4-year average of $35.8 million and a median of $37.6 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities slipped 5.37% in 2022, then slumped 63.75% in 2024.
• A 4-year view of Other Non-Current Liabilities shows it stood at $50.3 million in 2021, then tumbled by 35.58% to $32.4 million in 2022, then slumped by 59.21% to $13.2 million in 2023, then fell by 13.87% to $11.4 million in 2024.
• Business Quant data shows RLAY's Other Non-Current Liabilities at $11.4 million in Q1 2024, $13.2 million in Q4 2023, and $28.0 million in Q3 2023.